G
Gera Neufeld
Researcher at Technion – Israel Institute of Technology
Publications - 140
Citations - 24917
Gera Neufeld is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Angiogenesis & Vascular endothelial growth factor. The author has an hindex of 68, co-authored 134 publications receiving 24074 citations. Previous affiliations of Gera Neufeld include University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Vascular endothelial growth factor (VEGF) and its receptors
TL;DR: Recent developments that have widened considerably the understanding of the mechanisms that control V EGF production and VEGF signal transduction are focused on and recent studies that have shed light on the mechanisms by which VEGf regulates angiogenesis are reviewed.
Journal ArticleDOI
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
TL;DR: It is proposed that neuropilin-1 is a novel V EGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGf-induced angiogenesis.
Journal ArticleDOI
Structural characterization and biological functions of fibroblast growth factor
TL;DR: As expected from their structural relationship, both FGF and aFGF interact with the same receptor (7), thereby having similar, if not identical, properties.
Journal ArticleDOI
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
TL;DR: It is demonstrated using Northern analysis that treatment of various cell lines with IL-6 for 6-48 h results in a significant induction of VEGF mRNA, and it is shown that the 5′-UTR is important for the expression of V EGF.
Journal ArticleDOI
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.
Vivian Barry-Hamilton,Rhyannon Spangler,Derek Marshall,Scott Alan Mccauley,Hector Rodriguez,Miho Oyasu,Amanda Mikels,Maria Vaysberg,Haben Ghermazien,Carol Wai,Carlos Aurelio Garcia,Arleene C. Velayo,Brett Jorgensen,Donna Hiroko Tokuoka Biermann,Daniel Tsai,Jennifer Green,Shelly Zaffryar-Eilot,Alison Kay Holzer,Scott Ogg,Dung Thai,Gera Neufeld,Peter Van Vlasselaer,Victoria Smith +22 more
TL;DR: Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models and outperformed the small-molecule lysyl oxidase inhibitor β-aminoproprionitrile.